Andrew Guggenhime
Finanzdirektor/CFO bei VAXCYTE, INC.
Vermögen: 6 Mio $ am 31.05.2023
Profil
Andrew L.
Guggenhime is currently the Chairman at Caribou Biosciences, Inc. and the President & Chief Financial Officer at Vaxcyte, Inc. He previously worked as the Director at CardioDx, Inc. from 2014 to 2016, Independent Director at Metacrine, Inc. from 2018 to 2023, Assistant VP-Real Estate Capital Markets Group at Wells Fargo & Co., Chief Financial Officer & Senior Vice President at Neoforma, Inc. from 2000 to 2006, Chief Financial Officer at Calistoga Pharmaceuticals, Inc. from 2010 to 2011, Chief Financial Officer & Senior Vice President at Abbott Biotherapeutics Corp.
from 2008 to 2010, Chief Financial Officer & Senior Vice President at PDL BioPharma, Inc. from 2006 to 2008, and Chief Financial Officer at Dermira, Inc. from 2018 to 2020.
He also worked as a Vice President at Merrill Lynch & Co., Inc. from 1996 to 2000.
Mr. Guggenhime completed his undergraduate degree at Middlebury College and holds an MBA from Kellogg School of Management.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
VAXCYTE, INC.
0,09% | 20.05.2024 | 95 679 ( 0,09% ) | 6 Mio $ | 30.04.2024 |
METACRINE INC
-.--% | 03.02.2023 | 0 ( -.--% ) | - $ | 31.05.2023 |
| 15.04.2024 | 0 ( -.--% ) | - $ | 30.04.2024 |
Aktive Positionen von Andrew Guggenhime
| Unternehmen | Position | Beginn |
|---|---|---|
| VAXCYTE, INC. | Finanzdirektor/CFO | 01.05.2020 |
| CARIBOU BIOSCIENCES, INC. | Vorsitzender | - |
Ehemalige bekannte Positionen von Andrew Guggenhime
| Unternehmen | Position | Ende |
|---|---|---|
| METACRINE, INC. | Direktor/Vorstandsmitglied | 23.03.2023 |
| DERMIRA, INC. | Finanzdirektor/CFO | 01.05.2020 |
| CARDIODX INC | Finanzdirektor/CFO | 28.04.2014 |
Calistoga Pharmaceuticals, Inc.
 Calistoga Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Calistoga Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. The company was founded by Michael W. Gallatin, Roger Ulrich and Neil Giese in March 2006 and is headquartered in Tumwater, WA. | Finanzdirektor/CFO | 01.04.2011 |
Abbott Biotherapeutics Corp.
 Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | Finanzdirektor/CFO | 01.06.2010 |
Ausbildung von Andrew Guggenhime
| Middlebury College | Undergraduate Degree |
| Kellogg School of Management | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| WELLS FARGO & COMPANY | Finance |
| METACRINE, INC. | Health Technology |
| VAXCYTE, INC. | Health Technology |
| CARIBOU BIOSCIENCES, INC. | Health Technology |
| Private Unternehmen | 7 |
|---|---|
Neoforma, Inc.
 Neoforma, Inc. Medical DistributorsDistribution Services Neoforma, Inc. provides e-commerce services to healthcare industry. It also provides supply chain management solutions between hospitals and suppliers. The Company was founded in 1996 and is located in SanJose, CA. | Distribution Services |
PDL BioPharma, Inc.
 PDL BioPharma, Inc. BiotechnologyHealth Technology PDL BioPharma, Inc. engages in the business of developing innovative therapeutics and healthcare technologies. It operates under the Medical Devices and Income Generating Assets segments. The Medical Devices segment focuses on the sale and lease of the LENSAR laser system which includes equipment, patient interface devices, procedure licenses, training, installation, warranty, and maintenance agreements. The Income Generating Assets segment offers notes and other long-term receivables; royalty rights, hybrid notes, and royalty receivables; equity investments; and royalties from issued patents covering the humanization of antibodies. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Reno, NV. | Health Technology |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | Health Technology |
Calistoga Pharmaceuticals, Inc.
Calistoga Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Calistoga Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. The company was founded by Michael W. Gallatin, Roger Ulrich and Neil Giese in March 2006 and is headquartered in Tumwater, WA. | Health Technology |
CardioDx, Inc.
 CardioDx, Inc. Medical/Nursing ServicesHealth Services CardioDx, Inc. operates as a cardiovascular genomic diagnostics firm. It develops proprietary tests that improve treatment decisions and patient outcomes on coronary artery disease, cardiac arrhythmia, and heart failure. The company was founded by David L. Levison and Christopher R. Burrow in 2004 and is headquartered in Redwood, CA. | Health Services |
| Merrill Lynch & Co., Inc. | Finance |
Dermira, Inc.
 Dermira, Inc. Pharmaceuticals: MajorHealth Technology Dermira, Inc. is a biopharmaceutical company. It engages in the provision of therapies for chronic skin conditions. The company was founded by Thomas G. Wiggans, Eugene Andrew Bauer, Luis C. Peña, and Christopher M. Griffith on August 18, 2010 and is headquartered in Indianapolis, IN. | Health Technology |
